D. Naveen Kumar et al. / Tetrahedron Letters 47 (2006) 771–774
773
Cummings, J. N.; Polypradith, P.; Posner, G. H. Adv.
Pharmacol. 1997, 37, 253; (c) Haynes, R. K.; Vonwiller, S.
Acc. Chem. Res. 1997, 30, 73; (d) Robert, A.; Meunier, B.
Chem. Soc. Rev. 1998, 27, 273–279.
H H
H C
6
CH3
H
3
O
2. OÕNeill, P. M.; Searle, N. L.; Raynes, K. J.; Maggs, J. L.;
Ward, S. A.; Storr, R. C.; Park, B. K.; Posner, G. H.
Tetrahedron Lett. 1998, 39, 6065–6068.
2
O
9
H
1
O
O
3
4
. Snider, B. B.; Shi, Z. J. Org. Chem. 1990, 55, 5669–5671.
. (a) Sandler, J. S.; Colin, P. L.; Hooper, J. N. A.; Faulkner,
D. J. J. Nat. Prod. 2002, 65, 1258–1261; (b) Chen, Y.;
McCarthy, P. J.; Harmody, D. K.; OÕRourke, R. S.;
Chilson, K.; Selitrennikoff, C.; Pomponi, S. A.; Wright, A.
E. J. Nat. Prod. 2002, 65, 1509–1512; (c) Faulkner, D. Nat.
Prod. Rep. 2001, 18, 1–49; (d) Casteel, D. A. Nat. Prod.
Rep. 1999, 16, 55–73.
Figure 2. NOEÕs between the C-6 geminal protons and C-2 and C-9
methyls in compound 2.
Table 1. Antibacterial activity of compounds 1, 2 and 3 (MIC, lg/mL)
a
Microorganism
1
2
3
Ciprofloxacin
5
6
. (a) Davidson, B. S. J. Org. Chem. 1991, 56, 6722–6724; (b)
Qureshi, A.; Salva, J.; Harper, M. K.; Faulkner, D. J. J.
Nat. Prod. 1998, 61, 1539–1542; (c) Horton, P. A.;
Longley, R. E.; Kelly Borges, M. K.; McConnel, O. J.;
Ballas, L. M. J. Nat. Prod. 1994, 57, 1374–1381.
(
Gram +ve)
Bacillus subtilis
Bacillus sphaericus
Staphylococcus aureus
50 25
25 12.5 25
50 50
25
0.78
0.78
0.39
25
(
Gram Àve)
. (a) Jin, H.-X.; Liu; Zhang, Q.; Wu, Y. Tetrahedron Lett.
Klebsiella aerogenes
50 50
25
0.78
2
005, 46, 5767–5769; (b) Wasserman, H. H.; Wiberg, K.
B.; Larsen, D. L.; Parr, J. J. Org. Chem. 2005, 70, 105–109;
c) Tang, Y.; Dong, Y.; Vennerstrom, J. L. Med. Res. Rev.
004, 24, 425–448; (d) Yang, Y.-K.; Lee, S.; Tae, J. Bull.
Chromobacterium violaceum 25 25
Pseudomonas aeruginosa
12.5 0.39
— 0.78
—
—
(
2
a
Ciprofloxacin is used as positive control (standard).
Korean Chem. Soc. 2004, 25, 1307–1308; (e) Dussault, P.
H.; Trullinger, T. K.; Noor-e-Ain, F. Org. Lett. 2002, 4,
4
1
591–4593; (f) Jefford, C. W. Curr. Med. Chem. 2001, 8,
803–1826; (g) Murakami, N.; Kawanishi, M.; Itagaki, S.;
Table 2. Antifungal activity levels of compounds 1, 2 and 3
a
Microorganism
1
2
3
Clotrimazole
Horii, T.; Kobayashi, M. Bioorg. Med. Chem. Lett. 2002,
2, 69–72; (h) Murakami, N.; Kawanishi, M.; Itagaki, S.;
Horii, T.; Kobayashi, M. Tetrahedron Lett. 2001, 42,
281–7285; (i) McCullough, K. J.; Nojima, M. Curr. Org.
1
A
B
A
B
A
B
Aspergillus niger
Rhizopus oryzae
7
8
11
12
6
6
9
8
8
8
12 26
11 23
7
Chem. 2001, 5, 601–636; (j) Dussault, P. H.; Eary, C. T.;
Lee, R. J.; Zope, U. R. J. Chem. Soc., Perkin Trans. 1
1999, 2189; (k) Dussalut, P. H.; Eary, C. T. J. Am. Chem.
Soc. 1998, 120, 7133.
(
A = 30 lg/mL, B = 100 lg/mL); inhibitory zone diameters are in
millimetre.
a
Clotrimazole is used as positive control (standard).
7
8
. (a) Rieche, A.; Bischoff, C. Chem. Ber. 1962, 95, 77–82; (b)
Milas, N. A.; Mageli, O. L.; Golubovic, A.; Arndt, R. W.;
Ho, J. C. J. J. Am. Chem. Soc. 1963, 85, 222–226.
. Gbara-Haj-Yahia, I.; Zvilichovsky, G.; Seri, N. J. Org.
Chem. 2004, 69, 4135.
of 1, 2 and 3 following the standard procedure18 and this
revealed moderate inhibition against Aspergillus niger
and Rhizopus oryzae.
9. (a) Shashidhar Kumar, A.; Bhaket, P.; Rao, B. V.
ARKIVOC 2005, 74–81; (b) Kumar, A. S.; Haritha, B.;
Rao, B. V. Tetrahedron Lett. 2003, 44, 4261; (c) Rao, B.
V.; Rao, A. S. Synth. Commun. 1995, 1531. For the Birch
reduction of 2-picoline followed by hydrolysis, see: (d)
Kumar, D. N.; Rao, B. V. Tetrahedron Lett. 2004, 10,
In conclusion, we have demonstrated the synthesis
of new trans-1,8,12,13-tetraoxadispiro[4.1.4.2]tridecanes
and established the stereochemical outcome of the reac-
tion by NMR spectroscopy of each compound. Cur-
rently, studies are in progress to improve the yields, to
synthesise other analogues and to complete the evalua-
tion of their biological activity.
2
227.
1
1
1
0. (a) Allen, P. R.; Brimble, M. A.; Prabaharan, H. J. Chem.
Soc., Perkin Trans. 1 2000, 379; (b) Brimble, M. A.; Fares,
F. A. Tetrahedron 1999, 55, 7661–7706.
1. In most cases nearly 60% of 8 was recovered and the yields
quoted are calculated on the basis of starting material
recovery.
Acknowledgements
2. Analytical data for compounds 1, 2 and 3.
À1
Compound 1: White solid: mp 50–52 °C; IR (KBr, cm ):
D.N.K. and N.S. thank the UGC, New Delhi, for finan-
cial assistance (S.R.F.). The authors thank Dr. K. Bha-
nu Prakash, for helping with the energy calculations and
Dr. J. S. Yadav and Dr. A. C. Kunwar, for their support
and encouragement.
2
1
965, 2930, 2865, 1725, 1460, 1435, 1340, 1190, 1110, 1065,
1
010, 925, 900; H NMR (300 MHz, CDCl ): d 4.00–3.87
3
1
3
(
m, 4H), 2.86 (s, 2H), 2.32–1.82 (m, 8H); C NMR
(
75 MHz, CDCl ): d 114.89, 67.83, 51.43, 31.78, 24.42;
3
+
FAB-MS m/z: 187 [M+1] ; accurate mass calcd for
+
[
M+1] (C
Compound 2: White solid: mp 53 °C; IR (CHCl
2972, 2932, 1736, 1698, 1457, 1386, 1322, 1257, 1206, 1180,
9 17 4
H O ) = 187.0970, found: 187.0976.
À1
, cm ):
3
References and notes
1
1
142, 1120, 1062, 939, 892; H NMR (200 MHz, CDCl ):
3
1
. (a) Jefford, W.; Vicente, M. G. H.; Jacquier, Y.; Favarger,
F.; Marenda, J.; Millason-Schmidt, P.; Brunner, G.;
Burger, U. Helv. Chim. Acta 1996, 79, 1475–1487; (b)
d 4.23–4.10 (m, 2H), 2.84 (s, 2H), 2.30–1.97 (m, 6H), 1.54–
13
1.33 (m, 2H), 1.27 (d, 6H, J = 6 Hz); C NMR (75 MHz,
CDCl ): d 114.92, 75.29, 53.10, 32.21, 32.07, 20.46; ES-MS
3